URochester Medicine / Labs / Bidlack Lab / Publications

Publications

1. Daher F
2. Fukushima CT
3. Ingebretsen EA
4. Bidlack JM
5. Atack JR
6. Popa MO
7. Fogaça MV
Negative allosteric modulation of α5-GABA A receptors engages dynamic cortical glutamatergic and GABAergic mechanisms underlying adaptive behavior in mice.; bioRxiv : the preprint server for biology. 2026 Jan 16.
1. Aldrich JV
2. Yakovlev DY
3. Coleman JS
4. Senadheera SN
5. Stacy HM
6. Eans SO
7. Knapp BI
8. Bidlack JM
9. McLaughlin JP
Optimization of the Macrocyclic Tetrapeptide [D-Trp]CJ-15,208 to Prevent Stress-Induced Relapse of Cocaine-Seeking Behavior.; Molecules (Basel, Switzerland); Vol 30(19). 2025 Oct 05.
1. Grieble GM
2. Knapp BI
3. Bidlack JM
Mu Opioid Receptor Positive Allosteric Modulator BMS-986122 Confers Agonist-Dependent G Protein Subtype Signaling Bias.; Biochemistry. 2025 May 16.
1. Chang SL
2. Seth P
3. Zhu J
4. Pendyala G
5. Bidlack JM
6. Kumar S
The 27th Scientific Conference of the Society on NeuroImmune Pharmacology: New Delhi, India, March 15-18, 2023.; NeuroImmune pharmacology and therapeutics; Vol 2(2), pp. 187-244. 2023 Apr 10.
1. Kumar S
2. Yelamanchili S
3. Seth P
4. Bidlack JM
5. Pendyala G
6. Maggirwar S
7. Chang SL
The Neuroimmune Pharmacology of SARS-CoV-2.; Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 2021 Dec 22.
1. Bidlack JM
2. Chang SL
3. Fitting S
4. Gendelman HE
5. Gorantla S
6. Kumar S
7. Marcondes MCG
8. Meigs DD
9. Melendez LM
10. Sariyer IK
11. Yelamanchili S
The COVID-19 Pandemic: Reflections of Science, Person, and Challenge in Academic Research Settings.; Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 2021 Nov 26.
1. Dorval L
2. Knapp BI
3. Majekodunmi OA
4. Eliseeva S
5. Bidlack JM
Mice with high FGF21 serum levels had a reduced preference for morphine and an attenuated development of acute antinociceptive tolerance and physical dependence.; Neuropharmacology; Vol 202. 2021 Oct 26.
1. Kumar S
2. Pendyala G
3. Yelamanchili SV
4. Seth P
5. Maggirwar S
6. Bidlack JM
7. Chang SL
Society on NeuroImmune Pharmacology COVID-19 Virtual Workshop.; Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 2021 Jun 28.
1. Bartlett MJ
2. Mabrouk OS
3. Szabò L
4. Flores AJ
5. Parent KL
6. Bidlack JM
7. Heien ML
8. Kennedy RT
9. Polt R
10. Sherman SJ
11. Falk T
The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced Dyskinesia.; International journal of molecular sciences; Vol 22(1). 2020 Dec 22.
1. Barnett ME
2. Knapp BI
3. Bidlack JM
Unique Pharmacological Properties of the Kappa Opioid Receptor Signaling Through Gαz as Shown with Bioluminescence Resonance Energy Tranfer.; Molecular pharmacology; Vol 98(4). 2020 Oct.
1. Stevenson GW
2. Giuvelis D
3. Cormier J
4. Cone K
5. Atherton P
6. Krivitsky R
7. Warner E
8. St Laurent B
9. Dutra J
10. Bidlack JM
11. Szabò L
12. Polt R
13. Bilsky EJ
Behavioral pharmacology of the mixed-action delta-selective opioid receptor agonist BBI-11008: studies on acute, inflammatory and neuropathic pain, respiration, and drug self-administration.; Psychopharmacology. 2020 Jan 07.
1. Stowell RD
2. Sipe GO
3. Dawes RP
4. Batchelor HN
5. Lordy KA
6. Whitelaw BS
7. Stoessel MB
8. Bidlack JM
9. Brown E
10. Sur M
11. Majewska AK
Author Correction: Noradrenergic signaling in the wakeful state inhibits microglial surveillance and synaptic plasticity in the mouse visual cortex.; Nature neuroscience. 2019 Nov 27.
1. Stowell RD
2. Sipe GO
3. Dawes RP
4. Batchelor HN
5. Lordy KA
6. Whitelaw BS
7. Stoessel MB
8. Bidlack JM
9. Brown E
10. Sur M
11. Majewska AK
Noradrenergic signaling in the wakeful state inhibits microglial surveillance and synaptic plasticity in the mouse visual cortex.; Nature neuroscience. 2019 Oct 21.
1. Bidlack JM
2. Knapp BI
3. Deaver DR
4. Plotnikava M
5. Arnelle D
6. Wonsey AM
7. Toh MF
8. Pin SS
9. Namchuk MN
In Vitro Pharmacological Characterization of Buprenorphine, Samidorphan, and Combinations Being Developed as an Adjunctive Treatment for Major Depressive Disorder.; The Journal of pharmacology and experimental therapeutics. 2018 Aug 14.
1. Callaghan CK
2. Rouine J
3. Dean RL
4. Knapp BI
5. Bidlack JM
6. Deaver DR
7. O'Mara SM
Antidepressant-like effects of 3-carboxamido seco-nalmefene (3CS-nalmefene), a novel opioid receptor modulator, in a rat IFN-α-induced depression model.; Brain, behavior, and immunity. 2017 Aug 24.
1. Lefever M
2. Li Y
3. Anglin B
4. Muthu D
5. Giuvelis D
6. Lowery JJ
7. Knapp BI
8. Bidlack JM
9. Bilsky EJ
10. Polt R
Structural Requirements for CNS Active Opioid Glycopeptides.; Journal of medicinal chemistry; Vol 58(15). 2015 Aug 13.
1. Li Y
2. St Louis L
3. Knapp BI
4. Muthu D
5. Anglin B
6. Giuvelis D
7. Bidlack JM
8. Bilsky EJ
9. Polt R
Can amphipathic helices influence the CNS antinociceptive activity of glycopeptides related to β-endorphin?; Journal of medicinal chemistry; Vol 57(6). 2014 Mar 27.
1. Sromek AW
2. Provencher BA
3. Russell S
4. Chartoff E
5. Knapp BI
6. Bidlack JM
7. Neumeyer JL
Preliminary pharmacological evaluation of enantiomeric morphinans.; ACS chemical neuroscience; Vol 5(2). 2014 Feb 19.
1. Bidlack JM
Mixed κ/μ partial opioid agonists as potential treatments for cocaine dependence.; Advances in pharmacology (San Diego, Calif.); Vol 69. 2014.
1. Provencher BA
2. Sromek AW
3. Li W
4. Russell S
5. Chartoff E
6. Knapp BI
7. Bidlack JM
8. Neumeyer JL
Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors.; Journal of medicinal chemistry; Vol 56(21). 2013 Nov 14.
1. Hoot MR
2. Sypek EI
3. Reilley KJ
4. Carey AN
5. Bidlack JM
6. McLaughlin JP
Inhibition of Gβγ-subunit signaling potentiates morphine-induced antinociception but not respiratory depression, constipation, locomotion, and reward.; Behavioural pharmacology; Vol 24(2). 2013 Apr.
1. VanAlstine MA
2. Wentland MP
3. Alvarez J
4. Cao Q
5. Cohen DJ
6. Knapp BI
7. Bidlack JM
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 9: Synthesis, characterization and molecular modeling of pyridinyl isosteres of N-BPE-8-CAC (1), a high affinity ligand for opioid receptors.; Bioorganic & medicinal chemistry letters; Vol 23(7). 2013 Apr 1.
1. Wentland MP
2. Jo S
3. Gargano JM
4. VanAlstine MA
5. Cohen DJ
6. Bidlack JM
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 8. High affinity ligands for opioid receptors in the picomolar Ki range: oxygenated N-(2-[1,1'-biphenyl]-4-ylethyl) analogues of 8-CAC.; Bioorganic & medicinal chemistry letters; Vol 22(24). 2012 Dec 15.
1. Neumeyer JL
2. Zhang B
3. Zhang T
4. Sromek AW
5. Knapp BI
6. Cohen DJ
7. Bidlack JM
Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.; Journal of medicinal chemistry; Vol 55(8). 2012 Apr 26.
1. Li Y
2. Lefever MR
3. Muthu D
4. Bidlack JM
5. Bilsky EJ
6. Polt R
Opioid glycopeptide analgesics derived from endogenous enkephalins and endorphins.; Future medicinal chemistry; Vol 4(2). 2012 Feb.
1. Dean RL
2. Eyerman D
3. Todtenkopf MS
4. Turncliff RZ
5. Bidlack JM
6. Deaver DR
Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats.; Pharmacology, biochemistry, and behavior; Vol 100(3). 2012 Jan.
1. Yeomans L
2. Muthu D
3. Lowery JJ
4. Martinez HN
5. Abrell L
6. Lin G
7. Strom K
8. Knapp BI
9. Bidlack JM
10. Bilsky EJ
11. Polt R
Phosphorylation of enkephalins: NMR and CD studies in aqueous and membrane-mimicking environments.; Chemical biology & drug design; Vol 78(5). 2011 Nov.
1. Zhang B
2. Zhang T
3. Sromek AW
4. Scrimale T
5. Bidlack JM
6. Neumeyer JL
Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.; Bioorganic & medicinal chemistry; Vol 19(9). 2011 May 1.
1. Hough LB
2. Nalwalk JW
3. Yang J
4. Conroy JL
5. VanAlstine MA
6. Yang W
7. Gargano J
8. Shan Z
9. Zhang SZ
10. Wentland MP
11. Phillips JG
12. Knapp BI
13. Bidlack JM
14. Zuiderveld OP
15. Leurs R
16. Ding X
Brain P450 epoxygenase activity is required for the antinociceptive effects of improgan, a nonopioid analgesic.; Pain; Vol 152(4). 2011 Apr.
1. Zhang T
2. Yan Z
3. Sromek A
4. Knapp BI
5. Scrimale T
6. Bidlack JM
7. Neumeyer JL
Aminothiazolomorphinans with mixed κ and μ opioid activity.; Journal of medicinal chemistry; Vol 54(6). 2011 Mar 24.
1. Lowery JJ
2. Raymond TJ
3. Giuvelis D
4. Bidlack JM
5. Polt R
6. Bilsky EJ
In vivo characterization of MMP-2200, a mixed δ/μ opioid agonist, in mice.; The Journal of pharmacology and experimental therapeutics; Vol 336(3). 2011 Mar.
1. Balboni G
2. Salvadori S
3. Marczak ED
4. Knapp BI
5. Bidlack JM
6. Lazarus LH
7. Peng X
8. Si YG
9. Neumeyer JL
Opioid bifunctional ligands from morphine and the opioid pharmacophore Dmt-Tic.; European journal of medicinal chemistry; Vol 46(2). 2011 Feb.
1. Conroy JL
2. Fang C
3. Gu J
4. Zeitlin SO
5. Yang W
6. Yang J
7. VanAlstine MA
8. Nalwalk JW
9. Albrecht PJ
10. Mazurkiewicz JE
11. Snyder-Keller A
12. Shan Z
13. Zhang SZ
14. Wentland MP
15. Behr M
16. Knapp BI
17. Bidlack JM
18. Zuiderveld OP
19. Leurs R
20. Ding X
21. Hough LB
Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling.; Nature neuroscience; Vol 13(3). 2010 Mar.
1. Fulton BS
2. Knapp BL
3. Bidlack JM
4. Neumeyer JL
Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors.; Bioorganic & medicinal chemistry letters; Vol 20(5). 2010 Mar 1.
1. Balboni G
2. Salvadori S
3. Trapella C
4. Knapp BI
5. Bidlack JM
6. Lazarus LH
7. Peng X
8. Neumeyer JL
Evolution of the Bifunctional Lead μ Agonist / δ Antagonist Containing the Dmt-Tic Opioid Pharmacophore.; ACS chemical neuroscience; Vol 1(2). 2010 Feb 17.
1. Decker M
2. Si YG
3. Knapp BI
4. Bidlack JM
5. Neumeyer JL
Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors.; Journal of medicinal chemistry; Vol 53(1). 2010 Jan 14.
1. Decker M
2. Fulton BS
3. Zhang B
4. Knapp BI
5. Bidlack JM
6. Neumeyer JL
Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands.; Journal of medicinal chemistry; Vol 52(23). 2009 Dec 10.
1. Wentland MP
2. Lou R
3. Lu Q
4. Bu Y
5. Denhardt C
6. Jin J
7. Ganorkar R
8. VanAlstine MA
9. Guo C
10. Cohen DJ
11. Bidlack JM
Syntheses of novel high affinity ligands for opioid receptors.; Bioorganic & medicinal chemistry letters; Vol 19(8). 2009 Apr 15.
1. Wentland MP
2. Lu Q
3. Ganorkar R
4. Zhang SZ
5. Jo S
6. Cohen DJ
7. Bidlack JM
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 7: syntheses and opioid receptor properties of cyclic variants of cyclazocine.; Bioorganic & medicinal chemistry letters; Vol 19(2). 2009 Jan 15.
1. Wentland MP
2. Lou R
3. Lu Q
4. Bu Y
5. VanAlstine MA
6. Cohen DJ
7. Bidlack JM
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.; Bioorganic & medicinal chemistry letters; Vol 19(1). 2009 Jan 1.
1. Keyari CM
2. Knapp BI
3. Bidlack JM
4. Lowey J
5. Bilsky EJ
6. Polt R
Glycosyl-enkephalins: synthesis and binding at the mu, delta & kappa opioid receptors. Antinociception in mice.; Advances in experimental medicine and biology; Vol 611. 2009.
1. Bidlack JM
2. Morris HH
Phenobarbital withdrawal seizures may occur over several weeks before remitting: human data and hypothetical mechanism.; Seizure; Vol 18(1). 2009 Jan.
1. Mathews JL
2. Smrcka AV
3. Bidlack JM
A novel Gbetagamma-subunit inhibitor selectively modulates mu-opioid-dependent antinociception and attenuates acute morphine-induced antinociceptive tolerance and dependence.; The Journal of neuroscience : the official journal of the Society for Neuroscience; Vol 28(47). 2008 Nov 19.
1. Mathews JL
2. Fulton BS
3. Negus SS
4. Neumeyer JL
5. Bidlack JM
In vivo characterization of (-)(-)MCL-144 and (+)(-)MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties.; Neurochemical research; Vol 33(10). 2008 Oct.
1. Fulton BS
2. Knapp BI
3. Bidlack JM
4. Neumeyer JL
Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors.; Bioorganic & medicinal chemistry letters; Vol 18(16). 2008 Aug 15.
1. Wentland MP
2. Sun X
3. Cohen DJ
4. Bidlack JM
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 6: Opioid receptor binding properties of cyclic variants of 8-carboxamidocyclazocine.; Bioorganic & medicinal chemistry; Vol 16(10). 2008 May 15.
1. Reed B
2. Bidlack JM
3. Chait BT
4. Kreek MJ
Extracellular biotransformation of beta-endorphin in rat striatum and cerebrospinal fluid.; Journal of neuroendocrinology; Vol 20(5). 2008 May.
1. VanAlstine MA
2. Wentland MP
3. Cohen DJ
4. Bidlack JM
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 5. Opioid receptor binding properties of N-((4'-phenyl)-phenethyl) analogues of 8-CAC.; Bioorganic & medicinal chemistry letters; Vol 17(23). 2007 Dec 1.
1. Peng X
2. Knapp BI
3. Bidlack JM
4. Neumeyer JL
In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.; Bioorganic & medicinal chemistry; Vol 15(12). 2007 Jun 15.
1. Zhang A
2. Li F
3. Ding C
4. Yao Q
5. Knapp BI
6. Bidlack JM
7. Neumeyer JL
Synthesis and pharmacological evaluation of 6,7-indolo/thiazolo-morphinans--further SAR of levorphanol.; Journal of medicinal chemistry; Vol 50(11). 2007 May 31.